Cystic fibrosis: 2 new treatments will be reimbursed

The Minister of Health, Olivier Véran, has just authorized the reimbursement of two innovative treatments against cystic fibrosis: Kaftrio and Symkevi.

At the request of the Minister of Health Olivier Véran, the Economic Committee for Health Products (CEPS) conducted negotiations with the American laboratory Vertex on the price of two drugs (Kaftrio® and Symkevi®) prescribed against cystic fibrosis. The Minister of Health announced this weekend that the negotiations had just resulted in an agreement on the price, which will allow 100% coverage of these two treatments by Health Insurance.

The reimbursement of these drugs should be effective in the next few days, said the minister during the 9th Interviews of the cystic fibrosis organized by the Vaincrelamuco association.

An improvement over existing drugs

Kaftrio® and Symkevi®, prescribed in combination with the drug Kalydeco®, have been granted by the High Authority for Health (HAS) an improvement in the actual benefit (ASMR) of level II and III respectively in the therapeutic management of cystic fibrosis in children over 12 years old, adolescents and adults. Level II and III ASMRs attest to an additional gain in efficacy, quality of life and tolerance demonstrated in clinical trials from the point of view of patients or healthcare professionals, compared to existing drugs. Ultimately, there are 5,000 patients who will be able to benefit from these innovative treatments.

“This means very concretely that patients will benefit from innovative and effective treatments, giving them the best chances of quality of life and increased life expectancy” declared the Minister of Health to the patient association, which s ‘was widely mobilized so that Kaftrio is present in French pharmacies, as it is already in Germany, Denmark, Ireland, Switzerland, Finland or Slovenia.

Read also :

Subscribe to the Top Santé Newsletter to receive the latest news for free

Source: by

*The article has been translated based on the content of by If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!

*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.

*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!